ea0029p708 | Diabetes | ICEECE2012
Ring A.
, Brand T.
, Macha S.
, Breithaupt-Groegler K.
, Simons G.
, Walter B.
, Woerle H.
, Broedl U.
Empagliflozin is a potent, highly selective sodium glucose cotransporter-2 inhibitor in development for treatment of type 2 diabetes mellitus. This randomized, placebo-controlled, double-blind study assessed the effects of empagliflozin on the QT interval. Thirty healthy subjects (14/16 female/male; mean [range] age 34.5 [1852] years) received single doses of 25 mg (within therapeutic range) and 200 mg (supratherapeutic) empagliflozin and 400 mg moxifloxacin as positive ...